Lead Product(s) : ZX-7101A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZX-7101A is a novel PA inhibitor developed by Zenshine Pharma. It has broad-spectrum activity against influenza A, B and highly lethal variants of influenza viruses.
Product Name : ZX-7101A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : ZX-7101A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PIKA recombinant COVID-19 vaccine is composed of PIKA adjuvant and recombinant trimeric SARS-CoV-2 spike (S) protein subunit antigen (CHO cells). It is an innovative prophylactic and therapeutics vaccine candidate against multiple SARS-CoV-2 variants.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZX-7101A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZX-7101A is a novel PA inhibitor developed by Zenshine Pharma. It has broad-spectrum activity against influenza A, B and highly lethal variants of influenza viruses.
Product Name : ZX-7101A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : ZX-7101A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SSD8432,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate SSD8432 and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.
Product Name : Xiannuoxin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : SSD8432,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 Vaccine
Details : PIKA COVID-19 vaccine is composed of PIKA adjuvant and a stable trimeric form of the recombinant SARS-CoV-2 spike (S) protein as the main antigen component of the vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ReCOV is a recombinant COVID-19 vaccine developed by the company using new adjuvants, protein engineering platforms and other technology platforms. Its adjuvant uses the self-developed new adjuvant BFA03.
Product Name : Recov
Product Type : Vaccine
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PIKA recombinant COVID-19 vaccine is a highly differentiated vaccine candidate with potential prophylactic and therapeutic benefits against COVID-19 infection.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bofutrelvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FB2001 (bofutrelvir) has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting.
Product Name : FB2001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Bofutrelvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deuremidevir Hydrobromide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Vigonvita Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of study indicate that two different doses of JT001 (remdesivir derivative VV116),a new oral nucleoside analog showed favorable safety and efficacy in the treatment of both moderate and severe COVID-19 patients, in comparison with standard th...
Product Name : JT001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Deuremidevir Hydrobromide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Vigonvita Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
Details : ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the Company's self-developed novel adjuvant BFA03.
Product Name : Recov
Product Type : Vaccine
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable